CN1634130A - Composition for preventing and treating women postmenopausal osteoporosis - Google Patents
Composition for preventing and treating women postmenopausal osteoporosis Download PDFInfo
- Publication number
- CN1634130A CN1634130A CN 200410060215 CN200410060215A CN1634130A CN 1634130 A CN1634130 A CN 1634130A CN 200410060215 CN200410060215 CN 200410060215 CN 200410060215 A CN200410060215 A CN 200410060215A CN 1634130 A CN1634130 A CN 1634130A
- Authority
- CN
- China
- Prior art keywords
- menopause
- women
- osteosporosis
- calcium carbonate
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a composition for preventing and treating women postmenopausal osteoporosis which comprises soybean isoflavones, calcium carbonate, vitamin D3, and excipient. The composition is solid state, semi-solid state or liquid state product made by the forms of tablet, capsule, lozenge, pill, granule, and syrup.
Description
Technical field:
The present invention relates to a kind of compositions, relate in particular to a kind of compositions that is mainly used in prevention and treatment women's osteosporosis after menopause.
Background technology:
According to World Health Organization's report, osteoporosis has become the outstanding problem of harm humans health, occupies the 7th in world's commonly encountered diseases, the frequently-occurring disease.China has sufferers of osteoporosis face 9,000 ten thousand people approximately.
Osteoporosis is particularly serious to postmenopausal women's harm.Because body inner estrogen level sharply descends behind the postmenopausal women, the inhibition of osteoclast is weakened, the bone dissolving is quickened, and the bone formation effect dies down, so that causes bone calcium to lose osteoporosis in a large number.According to the Shanghai investigation, women's osteoporosis incidence reaches 90.5% more than 60 years old.After the osteoporosis, very easily cause fracture compound comminuteds such as compression fracture of spine, hip fracture, fracture of femoral neck, jeopardize the health and lives of elderly woman.
According to statistics, China has nearly 100,000,000 middle-aged women and 6,500 ten thousand elderly womans at present.Women's average life expectancy surpasses 75 years old, and be 49 years old average menopause.That is to say that women's life has 1st/3rd, spends after menopause.How preventing and treating postmenopausal women's osteoporosis, is the important topic that needs the whole society to pay close attention to.
To the control women's osteosporosis after menopause, present domestic emphasize merely " replenishing the calcium ".In recent years, prevent and treat osteoporotic various calcium preparation and (add appropriate vitamin D as calisanin, activated calcium, calcium carbonate
3) widely propagate and use.But the fact proves, can alleviate part patient's clinical symptoms though replenish the calcium, and replenishing the calcium merely after all can't be from basic prevention or the osteoporosis of curing the postmenopausal women.Countries such as U.S., Europe once used estrogen replacement therapy to prevent and treat primary disease, received certain effect, but found that life-time service estrogen can increase women breast cancer, ovarian cancer and cardiovascular diseases's danger, has to end this therapy.
Summary of the invention:
Osteoporotic problem appears after menopause easily in order to solve the women; the purpose of this invention is to provide a kind of compositions that can prevent and treat women's osteosporosis after menopause comprehensively, effectively, safely; the health of protection middle aged and aged women improves quality of life and quality of life.
The solution of the present invention realizes in the following manner:
A kind of compositions of preventing and treating women's osteosporosis after menopause, it includes following composition:
Soybean isoflavone
Calcium carbonate
Vitamin D
3
Excipient
Technical scheme of the present invention can realize in the following manner
A kind of compositions of preventing and treating women's osteosporosis after menopause, it is that preparation of raw material with following weight percent forms:
Soybean isoflavone 3-25%
Calcium carbonate 75-96%
Vitamin D
30.01-1%
Excipient is an amount of
The preferred technical solution of the present invention realizes in the following manner:
Soybean isoflavone 4-15%
Calcium carbonate 85-95%
Vitamin D
30.1-0.5%
Excipient is an amount of
Best-of-breed technology scheme of the present invention realizes in the following manner:
Soybean isoflavone 10%
Calcium carbonate 80%
Vitamin D
3100
Excipient is an amount of
Excipient is: microcrystalline Cellulose, carboxymethyl cellulose, starch.
The compositions of above-mentioned control women's osteosporosis after menopause is solid-state, semisolid or the liquid form product made from tablet, capsule, lozenge, pill, granule, syrup form.The application of above-mentioned composition in making health food, the application of above-mentioned composition in making medicine.
Soybean isoflavone is the Polyphenols mixture that extracts from Semen sojae atricolor; comprise 12 kinds of compositions; mainly contain genistein (genistein), Daidezin (daidzein) and Glycitein (glycitein), and the isoflavone aglycone of hexanoylization, malonylization, succinum transformation is arranged.Because its chemical constitution is a bis-phenol, and is structurally quite similar with the estrogen of human body ovarian secretion, and has the identical activity of estrogen, so be called " phytoestrogen " again.Over nearly 20 years, the various health-care of soybean isoflavone has caused that world medical circle pays close attention to widely.U.S., Europe, day and China scientist be through studying for a long period of time, certainly soybean isoflavone have anticancer, reduce Incidence of CHD, alleviate the Woman climacteric discomfort, prevent osteoporosis, effect such as prevention senile dementia.But the osteoporotic important function of its control postmenopausal women is not always by independent development and utilization.
Soybean isoflavone is a kind of natural sex, safety and phytoestrogen optionally of having concurrently.States such as U.S., Europe, day adopt soybean isoflavone to prevent and treat osteoporosis animal experiment proof and in the clinical curative effect that obtains in recent years.Through our confirmations that study for a long period of time, soybean isoflavone can make rat bone density increase, and osteocyte forms molten above disappearing, and has made the rehabilitation of a collection of elderly woman sufferers of osteoporosis face.
Calcium carbonate (Ca Co
3, Calcivm carbonate) in calcium be to keep the necessary material of human nerve, muscle, skeletal system, cell membrane and capillary permeability, be the Main Ingredients and Appearance that constitutes skeleton.
Vitamin D
3(C
2H
44O, Vitamin D
3) be a kind of fat soluble vitamin, can promote the absorption of human small intestine and renal tubules calcium, phosphorus, keep the balance of calcium in the blood, phosphorus, promote calcium, phosphorus to be present in the bone, but consumption can not be too big, otherwise can cause heavy poison.
Inventive point of the present invention is to utilize the phytoestrogen sample effect of soybean isoflavone, based on soybean isoflavone, makes the postmenopausal women replenish an amount of phytoestrogen, thereby prevents the secretion of osteoclast, and the minimizing sclerotin disappears molten, bone density improving.Simultaneously at calcium and vitamin D in China's middle aged and aged women food
3The insufficient characteristics of content are replenished calcium and vitamin D in right amount
3, effectively prevent bone loss, strengthen osteogenesis;
Make it to become control osteoporotic comprehensive, effective, easy health food of postmenopausal women or medicine.
Good effect of the present invention is:
1, adopts based on soybean isoflavone, be aided with the medical grade calcium carbonate and the vitamin D of reasonable dosage
3Thereby, solved menopausal women prevention of osteoporosis and treatment problem more all sidedly; Show through the influence test that influences test and the female rat femur weight of removal ovary to the female rat femur bone density of removal ovary: dosage and low dose group have clear improvement to the femoral bmd of the female rat of removal ovary in the invention, are better than the calcium carbonate group; Pure additional calcium carbonate then has little effect.The result also points out, and the present invention's low dose and middle dosage are better than heavy dose of group.
2, safe and reliable, effective, owing to this combination has no side effect, no teratogenesis, carcinogenesis, no dependence, safe and reliable, can take throughout one's life for the postmenopausal women.
3, alleviate the various discomforts of female climacteric syndrome, improve sleep;
4, blood lipid regulation and cholesterol raise human body high density lipoprotein (HDL), and low density lipoprotein, LDL (HDL) obviously reduces with cholesterol, triglyceride, thus the prevention cardiovascular and cerebrovascular disease;
5, slow down aging, skin whitening make mucocutaneous recovery elasticity;
6, prevention associated cancer;
7, control senile dementia (Alzheimer) also there is certain effectiveness.
The invention will be further described below in conjunction with embodiment:
Embodiment one: (following each raw material percentage composition is weight percentage)
Soybean isoflavone 3%
Calcium carbonate 90%
Vitamin D
31%
Carboxymethyl cellulose 6%
The production craft step of capsule aluminium foil carton packaging product of the present invention is as follows:
Heavyly advance percent and take by weighing soybean isoflavone, calcium carbonate, vitamin D respectively by above-mentioned
3, cellulose; In V-type bucket mix homogeneously, encapsulated, aluminium foil press mold packing, adorn capsule, adorn large, vanning.Irradiation sterilization, check, finished product warehouse-in.
Embodiment two: (following each raw material percentage composition is weight percentage)
Soybean isoflavone 10%
Calcium carbonate 75%
Vitamin D
30.1 iu
Microcrystalline Cellulose 14.9%
The bottled production and processing technology flow process of the special-shaped tablets film coating of above-mentioned prescription is as follows:
Take by weighing soybean isoflavone, calcium carbonate, vitamin D by component percentage composition in the above-mentioned prescription
3, cellulose; V-type bucket mix homogeneously, automatic tableting press tabletting, automatic film coating machine coating, drying, bottling, (60/bottle), vanning, irradiation sterilization, check, finished product warehouse-in
Embodiment three: (following each raw material percentage composition is weight percentage)
Soybean isoflavone 6%
Calcium carbonate 85%
Vitamin D
30.5%
Carboxymethyl cellulose 8.9%
Preparation technology is with embodiment one.
The zoopery result is as follows:
The effect of the present invention female Os Mus weight, bone density after zoopery confirms to have tangible increase spay, its experimental procedure and result are as follows:
1. select 60 of SD female rats for use, be the ablactation rat about 4 weeks of birth, body weight 340-350 gram is divided into 6 groups, 10 every group, specifically is grouped into:
(1) sham operated rats
(2) spay model group
(3) spay+low dose group of the present invention (L) is implemented 1 prescription, 50mg/kg/ day by invention
(4) dosage group (M) is implemented 1 prescription, 100mg/kg/ day by invention among spay+the present invention
(5) spay+high dose group of the present invention (H) is implemented 1 prescription, 200mg/kg/ day by invention
(6) spay+calcium carbonate group, VD
3Group 250mg/kg/ day
2. above-mentionedly respectively organize rat after one week of laundering period, fasting 12 hours is weighed, and by the body weight random packet, sub-cage rearing is drunk deionized water, raises and gives the normal feedstuff that does not contain the Semen sojae atricolor composition.
3. to (2), (3), (4), (5), (6) group row oophorectomy.
4. per os is irritated the stomach grouping and is tried thing, and the record intake, observes altogether 3 months.
5. body weight determination: fasting was measured body weight after 12 hours, and 1 time weekly, the body weight result is as shown in table 1 after 3 months.
Table 1 the present invention influences n=10, x ± s, g to removal ovary female rats body weight
The grouping March after body weight (g)
Sham operated rats 347.6 ± 25.5
Spay group 356.3 ± 26.4
L group 338.6 ± 24.6 of the present invention
M group 342.4 ± 25.3 of the present invention
H group 349.2 ± 26.5 of the present invention
Calcium carbonate group 352.2 ± 24.7
Because estrogen reduces sharply rat body weight is increased after the spay, the excision group is compared with normal group, L of the present invention group, M group, and P＜0.01 has significant difference; The calcium carbonate group is also organized apparently higher than L, M.
6. femur gravimetry
Each is organized rat and feeds after 3 months and put to death, and separates fl, and roasting key heavy to constant weight, weighing in 105 ℃ of baking boxs, the result is as follows:
Table 2 the present invention influences n=10, x ± s, g to the female rat femur weight of removal ovary
Group result
Sham operated rats 0.786 ± 0.062
Model control group 0.755 ± 0.072
L group 0.782 ± 0.063 of the present invention
M group 0.785 ± 0.065 of the present invention
H group 0.778 ± 0.066 of the present invention
Calcium carbonate group 0.762 ± 0.068
L group of the present invention, M group are compared with the contrast model group, P＜0.01; Compare P＜0.01 with the calcium carbonate group.
7. the mensuration of femur density:
Measure the bone density (BMD) of the feeding trial right femur mid point of rat and distal end after 3 months with French dual intensity X line borne densitometers (DEXA), the result is as follows:
Table 3 the present invention influences n=10, x ± s to the female rat femur bone density of removal ovary
Group result (BMD) group
Sham operated rats 0.162 ± 0.016
Model control group 0.141 ± 0.015
L group 0.161 ± 0.015 of the present invention
M group 0.163 ± 0.014 of the present invention
H group 0.158 ± 0.015 of the present invention
Calcium carbonate group 0.145 ± 0.013
The result shows that L group of the present invention, M group are compared with the contrast model group, P＜0.01; Compare with the calcium carbonate group, P＜0.01 all has significant difference.And the calcium carbonate group is compared with model control group, P＞0.01 then, no significant difference.As can be seen, dosage and low dose group have clear improvement to the femoral bmd of the female rat of removal ovary among the present invention, are better than the calcium carbonate group; Pure additional calcium carbonate then has little effect.The result also points out, and the present invention's low dose and middle dosage are better than heavy dose of group.
The present invention does not find toxic and side effects through animal experiment, no teratogenesis, carcinogenesis.
Claims (8)
1, a kind of compositions of preventing and treating women's osteosporosis after menopause, it contains following composition:
Soybean isoflavone
Calcium carbonate
Vitamin D
3
Excipient
2, according to the compositions of claims 1 described control women's osteosporosis after menopause, it is characterized in that: it is that preparation of raw material with following weight percent forms:
Soybean isoflavone 3-25%
Calcium carbonate 75-96%
Vitamin D
30.01-1%
Excipient is an amount of
3, according to claims 2 described control women's osteosporosis after menopause compositionss, it is characterized in that: it is that preparation of raw material with following weight percent forms:
Soybean isoflavone 4-15%
Calcium carbonate 85-95%
Vitamin D
30.1-1%
Excipient is an amount of
4, according to claims 2 or 3 described control women's osteosporosis after menopause compositionss, it is characterized in that: it is that preparation of raw material with following weight percent forms:
Soybean isoflavone 10%
Calcium carbonate 80%
Vitamin D
30.01-1%
Excipient is an amount of
5, according to claims 4 described control women's osteosporosis after menopause compositionss, it is characterized in that: excipient is: microcrystalline Cellulose, cross-linked carboxymethyl cellulose or starch.
6, control postmenopausal women osteoporosis compositions according to claim 5 is characterized in that: this compositions is solid-state, semisolid or the liquid form product made from tablet, capsule, lozenge, pill, granule, syrup form.
7, according to the application of claims 4 described control women's osteosporosis after menopause compositionss in the preparation medicine.
8, according to the application of claims 4 described control women's osteosporosis after menopause compositionss in the preparation health food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410060215 CN1634130A (en) | 2004-11-05 | 2004-11-05 | Composition for preventing and treating women postmenopausal osteoporosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410060215 CN1634130A (en) | 2004-11-05 | 2004-11-05 | Composition for preventing and treating women postmenopausal osteoporosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1634130A true CN1634130A (en) | 2005-07-06 |
Family
ID=34846214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410060215 Pending CN1634130A (en) | 2004-11-05 | 2004-11-05 | Composition for preventing and treating women postmenopausal osteoporosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1634130A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103251935A (en) * | 2013-05-28 | 2013-08-21 | 吉林玉参医药科技有限公司 | Medicinal composite containing cornu cervi pantotrichum and application thereof |
| CN103599096A (en) * | 2013-11-06 | 2014-02-26 | 苏州冉新生物技术有限公司 | Resveratrol tablet |
| CN115316669A (en) * | 2021-05-11 | 2022-11-11 | 深圳芙莱特营养与健康有限公司 | Nutrient composition |
-
2004
- 2004-11-05 CN CN 200410060215 patent/CN1634130A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103251935A (en) * | 2013-05-28 | 2013-08-21 | 吉林玉参医药科技有限公司 | Medicinal composite containing cornu cervi pantotrichum and application thereof |
| CN103599096A (en) * | 2013-11-06 | 2014-02-26 | 苏州冉新生物技术有限公司 | Resveratrol tablet |
| CN115316669A (en) * | 2021-05-11 | 2022-11-11 | 深圳芙莱特营养与健康有限公司 | Nutrient composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1306434A (en) | Compsn. for prevention and/or treatment of osteoporosis and alterations due to menopause syndrome | |
| CN101856114B (en) | Health food with bone intensity enhancing function and preparation method thereof | |
| CN1876003A (en) | Preparation method of effective parts of cynanchum bunaei and its use in treatment of insomina | |
| CN1215869C (en) | Black-bone chicken white phoenix preparation medicine and its preparing method | |
| CN1457808A (en) | Iron scale dendrobium compound preposition and preparation and use | |
| CN104116022B (en) | For composite heal-care food improving climacteric syndrome and preparation method thereof | |
| CN1136001C (en) | Hypertension-treating medicine | |
| CN1726991A (en) | Medication of treating by dysenorrhea, irregular menses, weakness after childbirth for women, and preparation method | |
| CN1823764A (en) | Medicinal composition containing strontium fuminate and vitamin D | |
| CN1220451C (en) | Health food | |
| CN1931280A (en) | Medicine for treating osteoporosis and its prepn process | |
| CN1634130A (en) | Composition for preventing and treating women postmenopausal osteoporosis | |
| CN103405755A (en) | Pharmaceutical composition for treating primary osteoporosis | |
| CN102626463A (en) | Natural medicine compound for increasing bone mineral density and preventing and treating osteoporosis | |
| CN100335051C (en) | Novel use of medicinal formulation capable of improving cerebral metabolism for preventing and treating osteoporosis | |
| CN1556101A (en) | Extraction technology of Hanbaicalein, medicinal composition and preparation technology of medicine | |
| CN1824086A (en) | Health protection capsule | |
| CN1286501C (en) | Medicine composition for treating stomach disease, its preparation method and use | |
| CN100496513C (en) | Bone density-increasing and senility-postponing capsule formulation | |
| CN1440790A (en) | Application of atractylodes rhizome oil in preparing medicine for osteoporosis | |
| CN1768760A (en) | Medicinal composition containing safflower total flavone and its preparation process and usage | |
| CN1254267C (en) | Medicine for treating gastral cavity pain and its preparation method | |
| CN1232283C (en) | Chinese drugs for treatment of coronary heart disease and angina pectoris | |
| CN1287807C (en) | Blood fat regulating drug or health food | |
| CN1193769C (en) | Health-care food with sobering function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |